http://jcps.bjmu.edu.cn

• 研究论文 • 上一篇    下一篇

比卡鲁胺胶囊/片健康人体生物等效性研究

王冰, 王本杰, 魏春敏, 孔祥麟, 郭瑞臣*   

  1. 山东大学齐鲁医院 临床药理研究所, 济南 250012
  • 收稿日期:2007-01-01 修回日期:2007-08-10 出版日期:2007-09-15 发布日期:2007-09-15
  • 通讯作者: 郭瑞臣*

Bioequivalence of bicalutamide capsules and tablets in Chinese healthy volunteers

Bing Wang, Ben-Jie Wang, Chun-Min Wei, Xiang-Lin Kong, Rui-Chen Guo*   

  1. Institute of Clinical Pharmacology, Qilu Hospital of Shandong University, Jinan 250012, China
  • Received:2007-01-01 Revised:2007-08-10 Online:2007-09-15 Published:2007-09-15
  • Contact: Rui-Chen Guo*

摘要: 目的 本文建立HPLC法测定比卡鲁胺血浓度, 研究比卡鲁胺胶囊(试验制剂)与比卡鲁胺片(参比制剂)在健康人体的药动学特征, 评价2制剂生物等效性。采用XB-C18色谱柱, 流动相乙腈-(6040, V/V), 检测波长272 nm48名健康志愿者, 随机分为2, 采用单周期平行试验设计, 单剂口服比卡鲁胺试验制剂或参比制剂50 mg, 采用高效液相色谱法测定比卡鲁胺血浓度, DAS2.0软件计算比卡鲁胺主要药代动力学参数。试验结果表明比卡鲁胺线性范围10~1200 ng·mL-1。比卡鲁胺试验制剂和参比制剂主要药动学参数分别为: t1/2 (138.36 ± 32.03)(146.12 ± 27.04) h, Tmax (17.17 ± 4.65)(16.92 ± 4.85) h, Cmax (910.83 ± 130.49)(868.71 ± 115.35) ng·mL-1, AUC0672 (172437.08 ± 3986.07)(176842.34 ± 35733.85) ng·mL-1·h, AUC0(179456.55 ± 43127.65)(185270.39 ± 39688.63) ng·mL-1·hCmax, AUC0672AUC0可信区间分别为(98.9%~100.7%), (98.8%100.6%)(99.7%101.7%)。比卡鲁胺胶囊相对生物利用度F97.51%。比卡鲁胺试验制剂和参比制剂具有生物等效性。

关键词: 比卡鲁胺, 比卡鲁胺, 比卡鲁胺, 药动学, 药动学, 药动学, HPLC, HPLC, HPLC, 生物等效性, 生物等效性, 生物等效性

Abstract:

Aim To establish a HPLC method for the determination of bicalutamide plasma concentration and to evaluate the bioequivalence of bicalutamide capsules (test) and tablets (reference). Methods A single oral dose of 50 mg bicalutamide capsules or tablets were given to 48 Chinese healthy volunteers in a one period parallel design test. Bicalutamide in plasma was analyzed using a XB-C18 column with a mobile phase of acetonitrile-water (60:40, V/V) and the dectection wavelength of272 nm and it is pharmacokinetic parameters were calculated and evaluated using DAS2.0. Results The linear range of bicalutamide was 10 1200 ng·mL-1. The main pharmacokinetic parameters of the test and reference were as the followings, t1/2 (138.36 ± 32.03) and (146.12 ± 27.04) h, Tmax (17.17 ± 4.65) and (16.92 ± 4.85) h, Cmax (910.83 ± 130.49) and (868.71 ± 115.35) ng·mL-1, AUC0-672 (172437.08 ± 3986.07) and (176842.34 ± 35733.85) ng·mL-1·h, and AUC0- (179456.55 ± 43127.65) and (185270.39 ± 39688.63) ng·mL-1·h, respectively. The two-one side t-test analysis showed that the confidence intervals of Cmax, AUC0-672 and AUC0- were (98.9% 100.7%), (98.8% 100.6%) and (99.7% 101.7%), respectively. Conclusion The relative bioavailability of bicalutamide capsules was 97.51%. The bioequivalence was demonstrated by the two-one side t-test.

Key words: Bicalutamide, Bicalutamide, Pharmacokinetics, Pharmacokinetics, HPLC, HPLC, Bioequivalence, Bioequivalence

中图分类号: 

Supporting: *Corresponding author. Tel.: 86-531-82169636